Website profile

Healiotwo

Medical news, education and information for physicians and health care professionals, presented by specialty and topic. From Healio and the Wyanoke Group.

  • 291articles · 30d
  • 1+ day agolatest article
  • Aug 14, 2026earliest in window
  • 77%with images
  • 85avg words
articles per day
Categories
  • Medical 286
  • Health 284
  • Health & Wellness 264
  • Beauty & Fitness 6
  • Food & Drink 4
  • Law & Government 3
  • Science & Technology 3
  • Sensitive Subjects 3

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

healiotwo
healio.com > pediatrics

Pediatrics News - Healio

4+ day, 1+ hour ago   (248+ words) Infectious Diseases in Children | Find pediatrics news articles, videos, blogs, books, Continuing Medical Education (CME), meeting coverage, and journal articles from the #1 online source for pediatricians, Pediatric Annals. CDC warns clinicians of surge in rabies activity The CDC issued an…...

healiotwo
healio.com > news > gastroenterology > 20/26/0909 > blood-test-targets-achilles-heel-of-crc-screening-detects-81-of-advanced-adenomas

Blood test targets ‘Achilles’ heel’ of CRC screening, detects 81% of advanced adenomas

3+ day, 18+ hour ago   (752+ words) Researchers have developed a blood-based assay that could help identify individuals with precursor lesions for colorectal cancer, a known limitation of many blood-based screening tests. The assay, known as DENEB, detected 81% of advanced adenomas, as well as 91% of CRC overall…...

healiotwo
healio.com > news > dermatology > 20/26/0911 > veterans-with-melanoma-may-face-higher-risk-for-parkinsons-disease

Veterans with melanoma may face higher risk for Parkinson’s disease

1+ day, 23+ hour ago   (414+ words) Veterans with melanoma have a 47% higher risk for developing Parkinson’s disease compared with veterans without melanoma, according to a study published in the Journal of the American Academy of Dermatology. These findings persisted even after adjusting for confounders, according to…...

healiotwo
healio.com > news > hematology-oncology > 20/26/0910 > a-chronic-condition-cancer-centers-continue-to-report-persistent-drug-shortages

‘A chronic condition’: Cancer centers continue to report persistent drug shortages

2+ day, 19+ hour ago   (562+ words) U.S. cancer centers continue to experience persistent shortages of medications that are foundational components of oncology care, according to survey results.All cancer centers that participated in a late-summer survey administered by National Comprehensive Cancer Network reported current shortages of at…...

healiotwo
healio.com > news > hematology-oncology > 20/26/0910 > cause-for-alarm-cancer-screening-rates-significantly-lower-for-adults-with-disabilities

‘Cause for alarm’: Cancer screening rates significantly lower for adults with disabilities

2+ day, 22+ hour ago   (443+ words) U.S. adults with disabilities are considerably less likely than those without them to undergo routine cancer screening, according to an analysis of national survey data.Researchers observed the largest screening gaps among individuals with self-care disabilities, such as difficulty dressing or…...

healiotwo
healio.com > news > hematology-oncology > 20/26/0909 > fda-oks-accelerated-approval-to-frontline-hyrnuo-for-nonsmall-cell-lung-cancer

FDA OKs accelerated approval to frontline Hyrnuo for non-small cell lung cancer

3+ day, 17+ hour ago   (55+ words) The FDA has granted accelerated approval to sevabertinib as first-line treatment for adults with locally advanced or metastatic non-squamous non-small cell lung cancer.The approval of sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals), which expands upon the agent’s existing indication…...

healiotwo
healio.com > news > hematology-oncology > 20/26/0908 > critical-window-stroke-risk-doubles-in-first-few-months-after-cancer-diagnosis

‘Critical window’: Stroke risk doubles in first few months after cancer diagnosis

4+ day, 19+ hour ago   (388+ words) People with invasive cancer may be more likely to experience ischemic stroke, according to results of a retrospective cohort study.Risk — which varied considerably by cancer type — appeared particularly elevated in the first few months after diagnosis....

healiotwo
healio.com > news > hematology-oncology > 20/26/0908 > truly-shocking-nearly-onethird-of-young-women-unscreened-for-cervical-cancer

‘Truly shocking’: Nearly one-third of young women unscreened for cervical cancer

4+ day, 19+ hour ago   (778+ words) The proportion of U.S. women who have never been screened for cervical cancer increased at a “troubling” rate over the past couple decades, according to researchers.As recently as a few years ago, nearly one-third of women aged 21 to…...

healiotwo
healio.com > news > hematology-oncology > 20/26/0908 > metabolic-syndrome-commonly-develops-in-men-with-prostate-cancer-receiving-adt-arpis

Metabolic syndrome commonly develops in men with prostate cancer receiving ADT, ARPIs

4+ day, 22+ hour ago   (521+ words) Approximately 40% of men with prostate cancer treated with concurrent androgen deprivation therapy and androgen receptor pathway inhibitors may develop metabolic syndrome within a year.A retrospective analysis of nearly 17,000 patients showed the first metabolic condition, usually hypertension, occurs within the…...

healiotwo
healio.com > news > hematology-oncology > 20/26/0904 > etcamah-grabs-fda-approval-for-advanced-breast-cancer-with-esr1-mutations

Etcamah grabs FDA approval for advanced breast cancer with ESR1 mutations

1+ week, 1+ day ago   (291+ words) The FDA has granted accelerated approval to camizestrant in combination with a CDK4/6 inhibitor for adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer. The approval for camizestrant (Etcamah, AstraZeneca) is dependent on the detection of an ESR1 mutation during…...